Literature DB >> 7702967

Circulating forms of immunoreactive parathyroid hormone-related protein for identifying patients with humoral hypercalcemia of malignancy: a comparative study with C-terminal(109-141)- and N-terminal(1-86)-region-specific PTHrP radioassay.

M Suehiro1, M Murakami, M Fukuchi.   

Abstract

We evaluated the circulating forms of immunoreactive PTHrP in 115 healthy subjects and 122 patients with malignant diseases by using radioassay systems (RAS) specific for the C-terminal (109-141) fragment of PTHrP (C-RAS) and for the N-terminal(1-86) (N-RAS). PTHrP levels in healthy controls ranged from 1.5 to 38.2 (mean: 24.5) pmol/L with the C-RAS and from 0.9 to 2.5 (mean: 1.7) pmol/L with the N-RAS. The ratio of circulating N-terminal fragment (N) to C-terminal fragment (C) of PTHrP was calculated to be about 1: 14.4 in the healthy subjects. Of the 122 patients with malignant diseases, 40 (32.8%) had circulating PTHrP levels undetectable with the N-RAS, but only 11 (9.0%) patients had levels undetectable with the C-RAS. Of the former 122 patients, 41 (33.6%) had high PTHrP as determined with the C-RAS, and 10 (8.2%) had high PTHrP as determined with the N-RAS. The former of these included only 8 (19.5%) HHM patients, while the latter included 8 (80.0%) HHM patients. The circulating N to C ratio was about 1: 70.7 in the HHM patients. The N and C obtained with the different RASs showed a close correlation (r = 0.86). The values also showed a close correlation with serum Ca; r = 0.75 for C-RAS and r = 0.81 for N-RAS. In addition, the correlations between the PTHrP reading obtained with the different RASs and serum Cr were: r = 0.42 with C-RAS and r = 0.26 with N-RAS. The circulating form of immunoreactive PTHrP fragments is therefore comprised mainly of PTHrP(109-141). In contrast, circulating concentrations of the PTHrP(1-86) fragment are very low, but detection of the PTHrP(1-86) fragment with the N-RAS is a more useful indicator of HHM with fewer false positive results and is less likely to be influenced by renal function than the detection of the PTHrP(109-141) fragment with C-RAS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7702967     DOI: 10.1007/bf03165025

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  17 in total

1.  Development and validation of an immunoradiometric assay of parathyrin-related protein in unextracted plasma.

Authors:  W A Ratcliffe; S Norbury; D A Heath; J G Ratcliffe
Journal:  Clin Chem       Date:  1991-05       Impact factor: 8.327

2.  Immunoreactivity of plasma parathyrin-related peptide: three region-specific radioimmunoassays and a two-site immunoradiometric assay compared.

Authors:  W A Ratcliffe; S Norbury; R A Stott; D A Heath; J G Ratcliffe
Journal:  Clin Chem       Date:  1991-10       Impact factor: 8.327

3.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

4.  Measurement of circulating parathyroid hormone-related protein in rats with humoral hypercalcemia of malignancy using a two-site immunoradiometric assay.

Authors:  G Gaich; W J Burtis
Journal:  Endocrinology       Date:  1990-09       Impact factor: 4.736

5.  Production and characterisation of monoclonal antibodies to parathyroid hormone-related protein.

Authors:  W A Ratcliffe; S Hughes; M G Gilligan; D A Heath; J G Ratcliffe
Journal:  J Immunol Methods       Date:  1990-02-20       Impact factor: 2.303

6.  Urinary excretion of parathyroid hormone-related protein fragments in patients with humoral hypercalcemia of malignancy and hypercalcemic tumor-bearing nude mice.

Authors:  H Imamura; K Sato; K Shizume; T Satoh; K Kasono; M Ozawa; E Ohmura; T Tsushima; H Demura
Journal:  J Bone Miner Res       Date:  1991-01       Impact factor: 6.741

7.  Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy.

Authors:  A F Stewart; K L Insogna; D Goltzman; A E Broadus
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

8.  Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia.

Authors:  M R Pandian; C H Morgan; E Carlton; G V Segre
Journal:  Clin Chem       Date:  1992-02       Impact factor: 8.327

9.  Levels of parathyroid hormone-related protein in hypercalcemia of malignancy: comparison of midregional radioimmunoassay and two-site immunoradiometric assay.

Authors:  E Blind; F Raue; T Meinel; M Bucher; C Manegold; W Ebert; I Vogt-Moykopf; R Ziegler
Journal:  Clin Investig       Date:  1993-01

10.  Malignancy-associated hypercalcemia: evaluation with a cytochemical bioassay for parathyroid hormone.

Authors:  D Goltzman; A F Stewart; A E Broadus
Journal:  J Clin Endocrinol Metab       Date:  1981-11       Impact factor: 5.958

View more
  3 in total

1.  PTHrP-related Hypercalcaemia in Infancy and Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).

Authors:  Nardeen Kodous; Guido Filler; Ajay Parkash Sharma; Tamara Angela Van Hooren
Journal:  Can J Kidney Health Dis       Date:  2015-05-11

2.  Cancer Diagnostics via Ultrasensitive Multiplexed Detection of Parathyroid Hormone-Related Peptides with a Microfluidic Immunoarray.

Authors:  Brunah A Otieno; Colleen E Krause; Abby L Jones; Richard B Kremer; James F Rusling
Journal:  Anal Chem       Date:  2016-09-08       Impact factor: 6.986

Review 3.  Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy.

Authors:  Jeremy S Frieling; Conor C Lynch
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.